BR0113577A - Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo - Google Patents
Empacotamento de partìculas de replicon de vìrus de rna de filamento positivoInfo
- Publication number
- BR0113577A BR0113577A BR0113577-5A BR0113577A BR0113577A BR 0113577 A BR0113577 A BR 0113577A BR 0113577 A BR0113577 A BR 0113577A BR 0113577 A BR0113577 A BR 0113577A
- Authority
- BR
- Brazil
- Prior art keywords
- rna virus
- packaging systems
- replicon particle
- virus replicon
- particle packaging
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
- C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
"EMPACOTAMENTO DE PARTìCULAS DE REPLICON DE VìRUS DE RNA DE FILAMENTO POSITIVO". A presente invenção refere-se de forma geral a polinucleotídeos recombinantes, a vetores de expressão e a sistemas de empacotamento de vírus de RNA de filamento positivo (psRNAV) recombinantes. Os sistemas de empacotamento são baseados na expressão de funções auxiliadoras através da co-infecção de vetores de poxvírus recombinantes que compreendem polinucleotídeos recombinantes. São descritos os métodos para obtenção de partículas de replicon de psRNAV utilizando estes sistemas de empacotamento. São fornecidas composições e formulações farmacêuticas imunogênicas que compreendem partículas de replicon da invenção. São também fornecidos os métodos para gerar uma resposta imunológica ou para produzir um efeito farmacêutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22890600P | 2000-08-29 | 2000-08-29 | |
PCT/US2001/041888 WO2002018585A2 (en) | 2000-08-29 | 2001-08-28 | Packaging of positive-strand rna virus replicon particles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113577A true BR0113577A (pt) | 2004-07-06 |
Family
ID=22859031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113577-5A BR0113577A (pt) | 2000-08-29 | 2001-08-28 | Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo |
Country Status (13)
Country | Link |
---|---|
US (2) | US7034141B2 (pt) |
EP (1) | EP1326990B1 (pt) |
JP (1) | JP2004507249A (pt) |
KR (1) | KR20030074594A (pt) |
CN (1) | CN1250731C (pt) |
AT (1) | ATE373721T1 (pt) |
AU (2) | AU2001293222B2 (pt) |
BR (1) | BR0113577A (pt) |
CA (1) | CA2424052A1 (pt) |
DE (1) | DE60130569D1 (pt) |
IL (1) | IL154169A0 (pt) |
MX (1) | MXPA03001680A (pt) |
WO (1) | WO2002018585A2 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU2001293222B2 (en) * | 2000-08-29 | 2007-09-20 | Wyeth Holdings Corporation | Packaging of positive-strand RNA virus replicon particles |
WO2002072803A2 (en) * | 2001-03-09 | 2002-09-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Subgenomic replicons of the flavivirus dengue |
US7045335B2 (en) * | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
SI1407033T1 (sl) * | 2002-05-16 | 2006-06-30 | Bavarian Nordic As | Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA) |
US20040053225A1 (en) * | 2002-09-13 | 2004-03-18 | Large Scale Biology Corporation | Enhancement of virus induced gene silencing (VIGS) through viral-based expression of inverted-repeats |
AU2003293675B2 (en) | 2002-11-25 | 2009-04-23 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ATI promoters |
EP1608762B1 (en) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
WO2004087201A2 (en) * | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
ES2222095B1 (es) * | 2003-07-02 | 2005-11-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia | Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones. |
AU2004257214B2 (en) * | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
FR2887259B1 (fr) * | 2005-06-21 | 2007-09-14 | Agronomique Inst Nat Rech | CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES |
EP1835031A1 (en) * | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
CA2689588C (en) | 2007-06-21 | 2016-08-23 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
CN101226196B (zh) * | 2008-02-02 | 2012-05-09 | 南方医科大学 | 一种检测ⅱ型登革病毒ns1抗原的免疫诊断试剂盒 |
WO2010039649A2 (en) * | 2008-10-03 | 2010-04-08 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus-based system for production of hepatitis c virus (hcv) |
CN101551393B (zh) * | 2009-04-02 | 2012-09-19 | 南方医科大学 | 一种检测ⅳ型登革病毒ns1抗原的免疫诊断试剂盒 |
CN104513820B (zh) * | 2013-09-30 | 2017-08-04 | 中国人民解放军军事医学科学院微生物流行病研究所 | DNA片段及其在制备H5N1亚型流感Guassia荧光素酶报告病毒中的应用 |
WO2015118146A1 (en) | 2014-02-10 | 2015-08-13 | Univercells Nv | System, apparatus and method for biomolecules production |
EP3310368A4 (en) * | 2015-06-19 | 2018-12-19 | Seracare Life Sciences Inc. | Sindbis control virus |
PL3407910T3 (pl) | 2016-01-29 | 2022-08-16 | Bavarian Nordic A/S | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2018023473A1 (zh) * | 2016-08-03 | 2018-02-08 | 台湾生物制剂股份有限公司 | 以整体表现细胞作为抗原载体及其于制备疫苗或诊断试剂及筛选单株抗体的应用 |
WO2019115090A1 (en) * | 2017-12-15 | 2019-06-20 | Intervet International B.V. | Multivalent feline vaccine |
US11167027B2 (en) | 2017-11-06 | 2021-11-09 | Intervet Inc. | Multivalent feline vaccine |
CN109806390A (zh) * | 2019-01-07 | 2019-05-28 | 康希诺生物股份公司 | 一种SamRNA疫苗及其制备方法 |
CN109943590B (zh) * | 2019-04-18 | 2022-11-18 | 西南大学 | 一种复制缺陷型猪圆环病毒、其制备方法及应用 |
EP3782465B1 (en) | 2019-08-23 | 2023-08-30 | Universität Potsdam | Transgenic zebrafish model for stroke |
CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
AU2001293222B2 (en) * | 2000-08-29 | 2007-09-20 | Wyeth Holdings Corporation | Packaging of positive-strand RNA virus replicon particles |
-
2001
- 2001-08-28 AU AU2001293222A patent/AU2001293222B2/en not_active Ceased
- 2001-08-28 CA CA002424052A patent/CA2424052A1/en not_active Abandoned
- 2001-08-28 BR BR0113577-5A patent/BR0113577A/pt not_active IP Right Cessation
- 2001-08-28 AU AU9322201A patent/AU9322201A/xx active Pending
- 2001-08-28 CN CNB018177395A patent/CN1250731C/zh not_active Expired - Fee Related
- 2001-08-28 MX MXPA03001680A patent/MXPA03001680A/es active IP Right Grant
- 2001-08-28 US US10/363,082 patent/US7034141B2/en not_active Expired - Fee Related
- 2001-08-28 AT AT01973668T patent/ATE373721T1/de not_active IP Right Cessation
- 2001-08-28 WO PCT/US2001/041888 patent/WO2002018585A2/en active IP Right Grant
- 2001-08-28 EP EP01973668A patent/EP1326990B1/en not_active Expired - Lifetime
- 2001-08-28 DE DE60130569T patent/DE60130569D1/de not_active Expired - Lifetime
- 2001-08-28 KR KR10-2003-7003106A patent/KR20030074594A/ko not_active Application Discontinuation
- 2001-08-28 JP JP2002522492A patent/JP2004507249A/ja active Pending
- 2001-08-28 IL IL15416901A patent/IL154169A0/xx unknown
-
2005
- 2005-12-08 US US11/297,316 patent/US20060141602A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030074594A (ko) | 2003-09-19 |
WO2002018585A2 (en) | 2002-03-07 |
WO2002018585A8 (en) | 2003-04-24 |
JP2004507249A (ja) | 2004-03-11 |
CN1250731C (zh) | 2006-04-12 |
EP1326990B1 (en) | 2007-09-19 |
CA2424052A1 (en) | 2002-03-07 |
US20060141602A1 (en) | 2006-06-29 |
US7034141B2 (en) | 2006-04-25 |
MXPA03001680A (es) | 2004-11-01 |
AU9322201A (en) | 2002-03-13 |
DE60130569D1 (de) | 2007-10-31 |
EP1326990A2 (en) | 2003-07-16 |
IL154169A0 (en) | 2003-07-31 |
ATE373721T1 (de) | 2007-10-15 |
CN1471583A (zh) | 2004-01-28 |
US20040029279A1 (en) | 2004-02-12 |
WO2002018585A3 (en) | 2003-01-23 |
AU2001293222B2 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113577A (pt) | Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo | |
PL398576A1 (pl) | Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne | |
EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
UY27218A1 (es) | Formulaciones de polvos para inhalación | |
IL145702A0 (en) | Recombination influenza viruses for vaccines and gene theraphy | |
IL106968A0 (en) | Potentiation of immunogenic response | |
BRPI0111830B8 (pt) | método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas | |
UA85536C2 (en) | Viral antigens | |
DE59410380D1 (de) | Endosomolytisch wirksame partikel | |
ATE419369T1 (de) | Chimäre mensch-rinder respiratory syncytial virus vakzinen | |
EP2066332A4 (en) | INFLUENZA VACCINE COMPRISING A MIXTURE OF MANNANE AND ANTIGEN OF INFLUENZA | |
FR2827605B1 (fr) | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin | |
GB2386072A (en) | Novel vaccine | |
JOP20220187A1 (ar) | لقاح فيروس الورم الحليمي البشري (hpv) | |
WO2002024897A3 (en) | Conditionally replicating viral vectors and their use | |
WO2002078631A3 (en) | Improved conditionally replicating vectors for inhibiting viral infections | |
UA95299C2 (ru) | Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с | |
WO2004092207A3 (en) | Respiratory syncytial virus (rsv) peptides | |
WO2003007986A3 (es) | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno | |
WO2004058807A3 (en) | Mhc class i restricted t-cell stimulating peptides from hepatitis b virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A , 9A E 10 ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |